Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3086653
Max Phase: Preclinical
Molecular Formula: C67H112N18O19
Molecular Weight: 1473.74
Molecule Type: Unknown
Associated Items:
ID: ALA3086653
Max Phase: Preclinical
Molecular Formula: C67H112N18O19
Molecular Weight: 1473.74
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC(C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)[C@@H](C)O)C(C)C)C(C)(C)C
Standard InChI: InChI=1S/C67H112N18O19/c1-32(2)25-39(68)54(92)79-43(26-33(3)4)64(102)85-24-18-22-46(85)60(98)76-40(21-17-23-72-66(70)71)56(94)84-52(67(11,12)13)63(101)74-36(9)53(91)77-42(28-47(69)89)55(93)73-29-48(90)75-44(30-86)58(96)80-45(31-87)59(97)78-41(27-38-19-15-14-16-20-38)57(95)81-49(34(5)6)61(99)83-51(37(10)88)62(100)82-50(35(7)8)65(103)104/h14-16,19-20,32-37,39-46,49-52,86-88H,17-18,21-31,68H2,1-13H3,(H2,69,89)(H,73,93)(H,74,101)(H,75,90)(H,76,98)(H,77,91)(H,78,97)(H,79,92)(H,80,96)(H,81,95)(H,82,100)(H,83,99)(H,84,94)(H,103,104)(H4,70,71,72)/t36-,37+,39-,40-,41-,42-,43-,44-,45-,46-,49-,50-,51-,52?/m0/s1
Standard InChI Key: DPMQPTRYJKWVTI-XJRSDUDESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1473.74 | Molecular Weight (Monoisotopic): 1472.8351 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Heard KR, Wu W, Li Y, Zhao P, Woznica I, Lai JH, Beinborn M, Sanford DG, Dimare MT, Chiluwal AK, Peters DE, Whicher D, Sudmeier JL, Bachovchin WW.. (2013) A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates., 56 (21): [PMID:24044354] [10.1021/jm400423p] |
Source(1):